Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

September 30, 2014

Conditions
Her2 Negative Breast Cancer Patients
Interventions
DRUG

MM-121

MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week

DRUG

Placebo

Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day

DRUG

Exemestane

Exemestane (25 mg) administered orally once per day

Trial Locations (33)

8035

Vall d'Hebrón University Hospital, Barcelona

8036

Hospital Clinic (Barcelona), Barcelona

8208

Hospital Parc Tauli - Barcelona, Barcelona

28007

Servicio de Oncología Médica / Hospital Universitario Gregorio Marañón, Madrid

28220

Puerta de Hierro, Madrid

34652

Pasco-Pinellas Oncology, New Port Richey

34952

Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie

35209

Achieve Clinical Research, Birmingham

35216

Achieve Clinical Research, Birmingham

37909

Tennessee Cancer Specialists Oncology Clinical Trials Center for Biomedical Research, Knoxville

Tennessee Cancer Specialists, Oncology Clincial Trials Center for Biomedical Research, Knoxville

46202

Indiana University Simon Cancer Center, Indianapolis

47905

Horizon Oncology Center, Lafayette

60612

Rush University Medical Center, Chicago

65189

Brustzentrum HS Kliniken Wiesbaden, Wiesbaden

80836

Onkogologisches zentrum Munich, Munich

85306

Arizona Center for Cancer Care, Glendale

90211

Beverly Hills Cancer Center, Beverly Hills

92025

Southwest Cancer Center, Escondido

92801

Pacific Cancer Medical Center, Anaheim

92879

Wilshire Oncology Medical Group, Inc., Corona

93454

Central Coast Medical Oncology Corporation, Santa Maria

94609

Hematology Oncology Associates, INC., Oakland

95124

San Jose Medical Center, San Jose

125271

Railway Clinical Hospital, Saint Petersburg

188663

Leningrad Regional Oncology Center, Saint Petersburg

197022

City Clinical Oncology Center, Saint Petersburg

02114

Massachusetts General Hospital, Boston

H1T2M4

Hopital Maissoneuve-Rosemont, Montreal

H3T 1E2

McGill University Jewish General Hospital, Montreal

H4J 1C5

Hopital du Sacre-Coeur de Montreal, Montreal

G1S 4L8

CHA St. Sacrement, Québec

Unknown

Medico-Diagnostically Center of International Institution of biological systems n.a.S.M., Berezina

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT01151046 - Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer | Biotech Hunter | Biotech Hunter